Digital Trials Digest, our quarterly newsletter
A quarterly look at what's new in ObvioGo, where decentralized trials are heading, and the partnerships shaping what's next — new Image Capture & Central Rating features, caregiver-collected growth data research, and what's coming in OG-2.10.
Issue 2: new Assent & Countersignature capabilities, ObvioGo's direct integration with Oracle Health and Life Sciences, Novotech's multi-trial licensing agreement, and SCOPE 2026 takeaways.
Issue 1: ObvioGo's new built-in eSignature, the Template Library and Out-of-Window Data Submissions features, caregiver-centric eDiary design, and how MiHelper accelerated a decentralized migraine study.
Discover how simplifying vaccine logistics can make scientific breakthroughs truly global — and why digital innovation is the missing link in equitable access.
As the FDA and HHS initiate a strategic review of the infant formula industry through Operation StorkSpeed, ObvioHealth’s experience in modernizing infant nutrition research offers a timely and relevant model for faster, safer, and more scalable clinical trials.
In response to rising healthcare demands, ObvioHealth is redefining clinical trials through decentralized models and patient-first technology that improves access, engagement, and data quality.
The FDA and OHRP have released new draft guidance providing recommendations for making the informed consent process as clear and comprehensive as possible for participants. Here's what you need to know.
Patient-reported outcomes are crucial components of every clinical trial—and they’re stronger and more accurate when captured electronically. Here’s what you need to know about PROs and ePROs.